Objective-The chemokine receptor CX 3 CR1 is an inflammatory mediator in vascular diseases. On platelets, its ligation with fractalkine (CX 3 CL1) induces platelet activation followed by leukocyte recruitment to activated endothelium. Here, we evaluated the expression and role of platelet-CX 3 CR1 during hyperlipidemia and vascular injury. Methods and Results-The existence of CX 3 CR1 on platelets at mRNA and protein level was analyzed by RT-PCR, quantitative (q)PCR, FACS analysis, and Western blot. Elevated CX 3 CR1 expression was detected on human platelets after activation and, along with increased binding of CX 3 CL1, platelet CX 3 CR1 was also involved in the formation of platelet-monocyte complexes. Interestingly, the expression of CX 3 CR1 was elevated on platelets from hyperlipidemic mice. Accordingly, CX 3 CL1-binding and the number of circulating platelet-monocyte complexes were increased. In addition, CX 3 CR1 supported monocyte arrest on inflamed smooth muscle cells in vitro, whereas CX 3 CR1-deficient platelets showed decreased adhesion to the denuded vessel wall in vivo. Conclusion-Platelets in hyperlipidemic mice display increased CX 3 CR1-expression and assemble with circulating monocytes. The formation of platelet-monocyte complexes and the detection of platelet-bound CX 3 CL1 on inflamed smooth muscle cells suggest a significant involvement of the CX 3 CL1-CX 3 CR1 axis in platelet accumulation and monocyte recruitment at sites of arterial injury in atherosclerosis. (Arterioscler Thromb Vasc Biol . 2012;32:1186-1193 .) the important role of the CX 3 CL1-CX 3 CR1 axis in atherosclerosis and vascular remodeling has been highlighted in several studies in hyperlipidemic mice. [22] [23] [24] [25] Given the integral role of platelets and the CX 3 CL1-CX 3 CR1 axis in the development of atherosclerosis and neointima formation, we investigated the expression and function of CX 3 CR1 on human and mouse platelets. The surface expression of CX 3 CR1 was upregulated after stimulation with thrombin and activated platelets reversibly associated with monocytic cells in a CX 3 CR1dependent manner. In hyperlipidemic mice, platelet CX 3 CR1 expression was increased, which was paralleled by an increase in circulating platelet-monocyte complexes (PMC). Finally, an involvement of CX 3 CR1 in platelet adhesion to sites of mechanical vascular injury was demonstrated. Taken together, these data add another dimension to the multifaceted role of platelets and the CX 3 CL1-CX 3 CR1 axis in vascular inflammation.
T he involvement of platelets in the onset and progression of atherosclerosis implies that the role of platelets extends beyond hemostasis and thrombosis. [1] [2] [3] Chronic or acute inflammatory conditions facilitate platelet attachment to the vessel wall, which is mediated by various endothelial adhesion molecules. 4 During interaction with the vessel wall, platelets secrete and deposit several key chemokines, such as CCL5 (RANTES), CXCL4 (platelet factor 4), and CXCL12 (stromal cell-derived factor-1a). 2, 5, 6 Notably, through heterophilic interactions with CCL5, deposited CXCL4 enhances the recruitment of monocytes leading to accelerated atherosclerosis in Apoe 2/2 mice. 7 In addition, platelet-bound CCL2 (monocyte chemoattractant protein-1) has been shown to contribute to the development of neointimal lesions by facilitating monocyte transmigration after vascular injury. 8 Besides carrying chemokines, platelets also express functional chemokine receptors, such as CCR1, CCR4, CXCR4, and CX 3 CR1. [9] [10] [11] [12] Although most chemokine receptors only weakly mediate platelet activation in vitro, the chemokine receptor CX 3 CR1 can play a role in platelet aggregation and subsequent interactions of platelets and leukocytes with the vessel wall. 13, 14 The specific ligand for CX 3 CR1 is CX 3 CL1 (fractalkine), a member of a unique class of transmembrane chemokines with a chemokine domain on a mucin-like stalk, which can exist in a membrane-anchored or proteolytically shed soluble form. 15, 16 Soluble CX 3 CL1 mediates chemotaxis, whereas the membrane-anchored form can directly support firm adhesion of leukocytes. 17 During inflammation, the expression of CX 3 CL1 is upregulated on endothelial cells and (neo-)intimal smooth muscle cells (SMC) exposed by arterial denudation injury. 15, 18, 19 Under those conditions, CX 3 CL1 may facilitate the adhesion and transmigration of monocytes, which circulate in increased numbers during hyperlipidemia. 20, 21 Accordingly,
Collection of Blood and isolation of Blood Cells
Blood platelets were isolated by centrifugation of platelet-rich plasma samples 28, 29 from healthy volunteers after informed consent and approval of the Ethical Committees in Aachen and Munich (Germany). Monocytes were prepared from human or mouse peripheral blood mononuclear cells by negative selection with MACS isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Mice were anesthetized by injection of ketamine and xylazine and blood was collected in EDTA by retroorbital puncture. Blood cells and platelets were analyzed in lysed whole blood by flow cytometry (see below).
determination of CX 3 Cr1 mrNa by rt-PCr and qPCr
Total RNA was isolated from human platelets and CX 3 CR1transfected or nontransfected HEK293 cells 30 using TRIzol reagent (Life Technologies), reverse transcribed, and amplified by PCR using specific intron-spanning primers for CX 3 CR1 and GAPDH as a house-keeping gene. To monitor donor-to-donor variation in CX 3 CR1 mRNA expression on platelets from healthy volunteers, qPCR using specific Taqman probes (Life Technologies) was performed and normalized to GAPDH. GP1B was used as a marker for platelets and CD45 as a marker for leukocytes.
Western Blot analysis
Total protein extract from human platelets or CX 3 CR1-transfected HEK293 cells was blotted on a nitrocellulose membrane, reacted with a rabbit anti-hCX 3 CR1 pAb (TP502; Torrey Pines Biolabs, Secaucus, NJ; 0.2 g/mL) followed by incubation with HRP antirabbit IgG and developed with ECL Reagent (Thermo Scientific, Germany). Stripped membranes were stained for -actin (Cell Signaling Technology, Beverly, MA) serving as a loading control.
Flow Cytometry
Platelet hCX 3 CR1 expression (CX 3 CR1-FITC, 4 g/mL) was confirmed by double staining with anti-3 integrin Ab (CD61-PerCP) and rat FITC-labeled IgG2b isotype control. A P-selectin Ab (CD62P-FITC) was used to confirm TRAP-6-induced platelet activation. For analysis of mouse platelets, P-selectin (CD62-FITC) and anti-aIIb integrin (CD41-APC) antibodies were used. AlexaFluor (AF)647-labeled CX 3 CL1 bound both h/mCX 3 CR1 ( Figure ID and IE in the online-only Data Supplement). Experiments were performed with a BD FACS Canto II flow cytometer and analyzed with FlowJo software. All data were corrected for nonspecific binding using the respective isotype controls.
Characterization of PMC Formation
(Activated) platelets were coincubated with THP-1 cells for 30 minutes at room temperature, immobilized on a poly-lysine-covered surface and subjected to scanning electron microscopy as described. 29, 31 For detection of PMC by FACS, antimouse CD41-PE, CD11b-PerCP5.5, and CD45-APC-Cy7 antibodies were used.
static adhesion and Parallel-Plate Flow Chamber adhesion assay
A 96-well plate was coated (4°C o/n) with human serum albumin (1%) or rhCX 3 CL1 (5 g/mL), washed with PBS, and blocked (1% BSA, 1 hour). Human platelets were loaded with calcein-AM ester (1 mol/L, 30 minutes at 37°C), washed, activated with TRAP-6 (15 mol/L, 5 minutes at 37°C), and treated with eptifibatide (0.5 g/ mL) allowing them to adhere as a monolayer. Part of the platelets was preincubated with a neutralizing anti-CX 3 CR1 Ab (5 g/mL, 30 minutes). Labeled platelets were added to the wells (30 minutes at 37°C) and then gently washed. Fluorescence was measured after every washing step with a spectrofluorimeter and expressed as fluorescence intensity units.
For flow chamber adhesion, whole blood was drawn in the presence of recombinant Hirudin (2.9 mol/L). Leukocytes in blood were labeled by the addition of rhodamine 6G (1 mol/L). A blocking anti-CX 3 CL1-antibody, isotype control, the CX 3 CR1antagonist F1-CX 3 CL1, 32 or heat-inactivated F1-CX 3 CL1 (all 5 g/mL) were added and incubated for 30 minutes at 37°C. SMC were cultured in 35-mm dishes, activated with TNFa (10 ng/mL) for 4 hours, and assembled into flow chambers. Whole blood was perfused for 4 minutes at 1.5 dynes/cm 2 , subsequently perfused with Hank's buffer containing HEPES (10 mmol/L), CaCl 2 , and MgCl 2 (1 mmol/L each) and 0.5% human albumin. Adherent fluorescent cells were manually counted in 6 fields and expressed as cells/mm 2 .
Production of F1-CX 3 CL1
A codon-optimized cDNA for the CX 3 CR1 agonist F1-CX 3 CL1 32 in pET26b was ordered at Genscript, expressed in BL21(DE3)Star cells and purified essentially as described. 7
Murine "Wire" Model of Carotid artery injury and intravital Microscopy
Female wild-type or Apoe 2/2 mice of the same age were fed an atherogenic diet for 1 week or 3 months before carotid wire injury. 8 To substitute with CX 3 CR1-deficient platelets, wild-type mice were treated with an antiplatelet antiserum 33 16 hours before reconstitution with 3310 8 CFSE-labeled-platelets from wild-type (n54) or CX 3 CR1-deficient mice (n54). Leukocytes were labeled by IV infusion of Rhodamine 6G, after which wire injury was performed. After 4 hours, adherent leukocyte and platelet counts at the site of injury were quantified using intravital microscopy. 7 immunohistochemistry Immunohistochemistry was performed for CX 3 CR1 (TP502; 10 g/ mL), CD62P (Santa Cruz, 20 g/mL), and CX 3 CL1 (R&D Systems, 15 g/mL) followed by FITC or Cy3 secondary antibody on the 5 m carotid artery sections. Fluorescence was visualized using a Leica DMLB fluorescence microscope and recorded with Diskus software (Hilgers, Königswinter, Germany).
statistical analysis
Data represent meanSE. Data were analyzed with an unpaired sample t test or 1-way ANOVA using Newman-Keuls post hoc test where applicable.
results

Platelets express Functional CX 3 Cr1
To explore the presence of CX 3 CR1 mRNA in human platelets, RT-PCR analysis was performed. A 100bp fragment was amplified from platelets and hCX 3 CR1-transfected HEK293 control cells, which corresponded to the theoretical size of the CX 3 CR1 product ( Figure 1A ). Detailed qPCR analysis indicated that CX 3 CR1 mRNA was present on platelets from all healthy volunteers with a respectable donor-to-donor variation ( Figure 1B) . The purity of the platelet mRNA preparation was assessed using GP1B and CD45 as platelet-and leukocyte-specific markers, respectively. Flow cytometry with specific antibodies and calibration beads confirmed the identity of our platelet preparations and failed to detect any CD45 1 cells (Figure IA-IC in the online-only Data Supplement). Western blotting with a polyclonal antibody directed against the N-terminal domain of hCX 3 CR1 revealed a protein band at approximately 55kDa for freshly isolated human platelets and peripheral blood mononuclear cells ( Figure 1C ). Interestingly, the variation of CX 3 CR1 between individuals on the protein level is much less pronounced than the variation on the mRNA level ( Figure 1B and 1C ). FACS analysis revealed the presence of CX 3 CR1 on the surface of resting human platelets and increased presentation after activation with the agonist TRAP-6 and with thrombin ( Figure  1D and 1E). This indicated that the CX 3 CR1 chemokine receptor is retained inside the platelet and directed to the membrane on activation. To assess ligand-binding capacity of platelet CX 3 CR1, we used the AF647-labeled chemokine domain of CX 3 CL1. Fluorescently labeled CX 3 CL1 bound to TRAP-6-activated platelets in a dose-dependent manner ( Figure 1F ). The specificity of the hCX 3 CR1 antibody and the AF647-labeled CX 3 CL1 was validated using human and mouse CX 3 CR1-transfected HEK293 cells and peripheral blood-isolated monocytes ( Figure ID and IE in the online-only Data Supplement).
CX 3 Cr1 Contributes to Platelet-Monocyte Complex (PMC) Formation
Incubation of THP-1 monocytic cells with TRAP-6-activated but not resting human platelets resulted in a significant PMC formation as shown by increased staining of the platelet marker CD61 in the monocyte-gated population (Figure 2A and 2C). The formation of platelet-leukocyte complexes was also observed in TRAP-6-treated whole blood ( Figure  IIA in the online-only Data Supplement). Electron microscopy revealed THP-1 cells covered with activated platelets ( Figure 2B ). To test whether platelet-CX 3 CR1 plays a role in PMC formation, platelets were preincubated with a CX 3 CR1antagonist F1-CX 3 CL1, 32 this significantly decreased the PMC formation ( Figure 2C ). The complete disruption of the PMC was achieved by their incubation with EDTA (10 mmol/L for 15 minutes, 37°C), indicating the reversibility of their formation. Similar observations were made for PMC formation in mouse whole blood ( Figure 2D) . Here, addition of EDTA (5 mmol/L, 30 minutes at RT) resulted in a notable reduction in size of the monocyte specific CD11b 1 population, indicative of platelets dissociating from the monocytes (Figure 2E ).
Hyperlipidemia increases Platelet-CX 3 Cr1 expression and is accompanied by PMC Formation
Circulating platelets have been shown to contribute to the development of atherosclerotic lesions by depositing platelet chemokines like CCL5 and CXCL4 in Apoe 2/2 mice. 5, 7 Here, we hypothesized that platelet activation during hyperlipidemia would result in increased expression of CX 3 CR1. Thus, CX 3 CR1 expression levels were determined on platelets in whole blood from wild-type, Apoe 2/2 , CX 3 CR1 G/G Apoe 2/2 , and Ldlr 2/2 mice. Compared to wild-type mice, platelets from hyperlipidemic Apoe 2/2 and Ldlr 2/2 mice displayed a marked increase of CX 3 CR1 on their surface ( Figure 3A and 3B ). Please note that platelets from CX 3 CR1 G/G Apoe 2/2 mice also showed increased green fluorescence possibly due to upregulation of the eGFP gene under the control of the CX 3 CR1 promoter. Upregulation of CX 3 CR1 on platelets was paralleled by increased expression of P-selectin indicating an elevated platelet activation state in hyperlipidemic mice ( Figure IIB in the online-only Data Supplement). Cholesterol, HDL, and LDL levels were comparable between hyperlipidemic Apoe 2/2 , CX 3 CR1 G/G Apoe 2/2 , and Ldlr 2/2 mice, yet were higher than those of wild-type (C57Bl/6) mice ( Figure IIC in the online-only Data Supplement). Accordingly, binding of AF647-CX 3 CL1 was significantly (P0.05) increased on platelets from Apoe 2/2 and also platelets from Ldlr 2/2 mice showed enhanced AF647-CX 3 CL1 binding, though not statistically significant ( Figure 3C ). Binding of AF647-CX 3 CL1 was absent on CX 3 CR1-deficient platelets ( Figure 3C ). The proinflammatory state in hyperlipidemic Apoe 2/2 and CX 3 CR1 G/G Apoe 2/2 mice resulted not only in CD11b 1 monocytosis ( Figure 3D ), consistent with previous findings, 20 but also in enhanced numbers of circulating PMC as shown by a significant increase (P0.05) in CD41 1 staining on monocytes ( Figure 3E ). PMC formation was significantly increased in Apoe 2/2 and Ldlr 2/2 and appeared to depend on CX 3 CR1, as these complexes were virtually absent in CX 3 CR1 G/G Apoe 2/2 mice despite their increased monocyte counts. Together, these data indicate that hyperlipidemia, associated with increased numbers of PMC, affects circulating platelets similarly as seen for platelet activation by classical agonists leading to increased functional CX 3 CR1 expression.
Platelet-CX 3 Cr1 enhances CX 3 CL1-Mediated adhesion of Platelets and of PMC to sMC
On arterial denudation, CX 3 CL1 expression is strongly upregulated on SMC 34 and mediates interactions with CX 3 CR1-expressing cells. 24 In the following experiment, adhesion of TRAP-6-activated platelets to immobilized rhCX 3 CL1 was specifically increased by 35.8%6.13 ( Figure 4A ) (P0.05) as compared with adhesion to plastic and human serum albumin and as shown by preincubation with a CX 3 CR1 neutralizing antibody. In agreement with this finding, adhesion of nonactivated platelets to rhCX 3 CL1 was almost absent (not shown). Together, these data indicate that CX 3 CR1 exposed on activated platelets is able to stably bind CX 3 CL1. In line, TNFa-stimulated SMC, which have been shown to express CX 3 CL1 on activation, 18 supported robust adhesion of blood leukocytes to smooth muscle cells only when platelets were activated by the addition of TRAP-6 ( Figure 4B ). The formation of platelet-leukocyte aggregates after platelet activation was confirmed by FACS analysis ( Figure IIA in the online-only Data Supplement). Pretreatment of the perfused SMC with a neutralizing CX 3 CL1 antibody blocked leukocyte adhesion, compared to an isotype control ( Figure  4B ). In addition, incubating the TRAP-6-activated whole blood with F1-CX 3 CL1 reduced stable leukocyte arrest to the same extent, indicating that the process was strongly mediated by the CX 3 CL1-CX 3 CR1 axis. No difference in leukocyte adhesion was observed after F1-CX 3 CL1-treatment in untreated whole blood (not shown). Control experiments with primary monocytes demonstrated that CX 3 CR1 expression on monocytes is not increased on stimulation with either TRAP-6 or thrombin ( Figure IID and IIE in the online-only Data Supplement) thus hinting at a specific contribution of CX 3 CR1 expressed on platelets.
To further demonstrate a role for platelet-CX 3 CR1 in the adhesion of platelets and leukocytes to the injured vessel wall, platelet-depleted wild-type mice were reconstituted with CX 3 CR1-deficient or wild-type platelets in a wire-injury denudation model using intravital microscopy. Interestingly, 4 hours after wire injury, in comparison to wild-type platelets, significantly fewer CX 3 CR1-deficient platelets adhered to the subendothelial matrix, although there was a trend toward decreased leukocyte accumulation ( Figure 4C and 4D ), suggesting a contribution of platelet-CX 3 CR1 to the adhesion of platelets to the exposed intima of the vessel wall.
CX 3 Cr1 expressing Platelets adhere to sMC on endothelial denudation
Platelet accumulation to the luminal surface of carotid arteries was subsequently investigated 1 day after wire-injury in wildtype, Apoe 2/2 and CX 3 CR1 G/G , Apoe 2/2 mice. After injury, a platelet monolayer covered the denuded surface and the lesion consisted primarily of luminally exposed SMC ( Figure 5 ). Immunostaining revealed that CX 3 CR1 and CD62P double positive platelets adhered to the denuded arterial wall ( Figure  5 ). In addition, CX 3 CR1-deficient platelets were still able to cover the denuded arterial wall 1 day after wire-injury but to a lesser extent ( Figure 5 ). Thus, these data support the findings from the platelet reconstitution experiment ( Figure 4C ) and further indicate that platelet-derived CX 3 CR1 may play a role in platelet adhesion to the subendothelial matrix during the acute stage of vessel injury.
Collectively, our data imply that platelets in hyperlipidemic Apoe 2/2 mice display an increased activation state characterized by overexpression of functional CX 3 CR1, reside in complex with monocytes in the circulation, and accumulate on SMC at sites of arterial denudation thereby facilitating additional leukocyte recruitment to the injured vessel.
discussion
In the present study, we investigated the contribution of platelet CX 3 CR1 on monocyte recruitment to denuded endothelium under hyperlipidemic conditions. The presence of functional platelet CX 3 CR1 was demonstrated before, but only in the context of adhesion to endothelial cells. [12] [13] [14] Here, we demonstrate that human and mouse platelets overexpress functional platelet CX 3 CR1 on activation or by hyperlipidemia triggering their adherence and subsequent monocyte recruitment to arterial lesions. Although the content of mRNA encoding CX 3 CR1 was found to differ considerably among individuals, the protein levels of CX 3 CR1 in donors were similar, indicating that platelet CX 3 CR1 is produced during the megakaryocytic stage. The increase in surface expression of CX 3 CR1 after activation by thrombin or during hyperlipidemic conditions implies that CX 3 CR1 is probably located primarily to the surface-connected canalicular system or to a-granules, similar to P-selectin. Thus, circulating platelets express substantial amounts of CX 3 CR1 when activated by inflammatory stimuli present in the blood stream. This appears in contrast with other platelet chemokine receptors, such as CCR4 and CXCR4, which are able to respond to their respective chemokines under resting conditions. 10 As known from literature, CX 3 CL1 is able to induce chemotaxis, adhesion, and cell signaling through CX 3 CR1. 16 We have demonstrated in an in vitro set up that CX 3 CR1 exposed on activated platelets can robustly bind fluorescently-labeled CX 3 CL1 in a dose-dependent manner. This interaction is specific and was confirmed also by its binding to peripheral blood-isolated monocytes and cells transfected with human or mouse CX 3 CR1.
It is well-established that platelets do not act as single players in the inflammatory game. For example, interaction of monocytes with platelets increases the adhesive properties of monocytes toward inflamed or atherosclerotic endothelium 5, 35 and platelets interact with adherent leukocytes through the adhesion receptor GP1B and the leukocyte integrin a M  2 (CD11b/ CD18). 36 An important finding in our study is that activated but not resting human platelets led to a significant platelet-THP-1 complex formation as measured by increased staining of the platelet marker CD61 in the monocyte-gated population and visualized in electron microscopy images. Platelet-CX 3 CR1 thus appears to play a notable role in PMC assembly, as preincubation of platelets with the CX 3 CR1-antagonist F1-CX 3 CL1 significantly decreased PMC formation. Similar observations could be made in mouse blood, because PMC formation during hyperlipidemia was dependent on CX 3 CR1. The formation of PMC was reversible, as the PMC were completely disrupted by EDTA treatment.
Upregulation of platelet CX 3 CR1 was observed in hyperlipidemic mice and was accompanied by increased expression of P-selectin, indicating an elevated platelet activation state in these mice. The previous observation that membrane-bound Stimulated SMC were preincubated with anti-CX 3 CL1 neutralizing mAb or isotype control (5 g/mL). Alternatively, the blood was treated with F1-CX 3 CL1 or heat-inactivated F1-CX 3 CL1 (5 g/mL). n 3 independent experiments. Intravital microscopy of denuded carotid artery, 4 hours after wire-injury (C, D). Platelet (C) or leukocyte counts (D) were expressed as adherent cells per mm 2 of damaged vessel area. CX 3 CL1 was able to induce CX 3 CR1-mediated platelet degranulation and P-selectin expression 13 thus enhancing platelet-leukocyte interactions appears to be consistent with our findings. Elevated surface expression of CX 3 CR1 on circulating platelets from hyperlipidemic mice leads to increased interactions of platelets with monocytic cells. Interestingly, platelets from CX 3 CR1 G/G Apoe 2/2 mice showed increased green fluorescence likely attributable to upregulation of the eGFP gene under the control of the CX 3 CR1 promoter. Cholesterol, HDL, and LDL levels were comparable between hyperlipidemic Apoe 2/2 , CX 3 CR1 G/G Apoe 2/2 and Ldlr 2/2 mice, yet were higher than those of wild-type mice. In addition, we observed elevated monocyte counts in hyperlipidemic mice consistent with previous findings 20 but also enhanced numbers of circulating PMC as a result of the proinflammatory state present in these animals. PMC formation was significantly increased in Apoe 2/2 and Ldlr 2/2 mice and appeared to depend on CX 3 CR1, as these complexes were not present in CX 3 CR1 G/G Apoe 2/2 mice, despite their increased monocyte counts.
In in vitro static adhesion assays, a pronounced role of platelet CX 3 CR1 in the adhesion to immobilized CX 3 CL1 was observed, which is consistent with a recent study showing CX 3 CR1-dependent binding of platelets to CX 3 CL1-coated microbeads. 14 Furthermore, under shear flow in whole blood, a robust adhesion of leukocytes on activated SMC, which express CX 3 CL1 after stimulation, 18, 19 was recorded only after activation of the blood platelets with TRAP-6, hinting at an involvement of platelet-leukocyte interactions in this process. The formation of platelet-leukocyte complexes after TRAP-6-treatment of whole blood was confirmed by flow cytometry. By blocking CX 3 CL1 or CX 3 CR1, we could show that the leukocyte adhesion strongly depended on the CX 3 CL1-CX 3 CR1 axis. In mouse models of vascular injury, a reduction of platelet adhesion to the denuded carotid artery wall was observed in the absence of CX 3 CR1. This suggests that CX 3 CL1-CX 3 CR1 serves as a functional adhesion receptor pair mediating shear-resistant platelet interaction with intimal SMC. These above findings might conflict with those from a study by Liu et al 24 showing no difference in platelet adhesion onto wire-injured femoral arteries between CX 3 CR1 2/2 and wild-type mice. However, these differences may arise from the use of nonhyperlipidemic C57Bl/6 mice in this study, in which the minor expression of CX 3 CR1 2/2 on platelets might have led to an underestimation of its role in vascular injury.
In conclusion, this study clearly shows that human and mouse platelets carry the functional chemokine receptor CX 3 CR1, which can be enhanced on the surface on activation by inflammatory stimuli, similarly as seen for platelet activation by classical agonists. The present data indicate that under conditions of hyperlipidemia, platelets with a hyperreactive state and elevated CX 3 CR1 surface expression, in the context of increased circulating monocyte counts, are recruited alone or in a complex with monocytes to the site of inflammation, thus contributing to the complexity of arterial lesions and accelerating their development.
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